Mycosis fungoides and Sezary syndrome: Therapeutic approach and outcome in 113 patients

International Journal of Dermatology

Volumn 44, Issue 7, 2005, Pages 559-565

  Anadolu, Rana Yavuzer ^a,b,c,d   Birol, Ahu ^a,b,c   Şanli, Hantice ^a,b,c   Erdem, Cengizhan ^a,b,c   Türsen, Ümit ^a,b,c  

^a ANKARA UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c MERSIN UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETRETIN; FLUDARABINE; GEMCITABINE; METHOXSALEN; PENTOSTATIN; PREDNISOLONE; STEROID; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PUVA; SCHOOL CHILD; SEZARY SYNDROME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; DEOXYCYTIDINE; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PENTOSTATIN; PUVA THERAPY; SEZARY SYNDROME; TREATMENT OUTCOME;

EID: 21844472754     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02033.x     Document Type: Article

References (34)

1. Kerl H, Cerroni L, Burg G. The morphological spectrum of T-cell lymphomas of the skin. Semin Diag Pathol 1991; 8: 55.
2. Jörg B, Kerl H, Thiers BH, et al. Therapeutic approaches in cutaneous T-cell lymphoma. Dermatol Clin 1994; 12: 433.
3. Teixeira F, Ortiz-Plata A. Do environmental factors play any role in the pathogenesis of mycosis fungoides and Sezary syndrome. Int J Dermatol 1994; 33: 770-772.
4. Pimpinelli N, Santucci M, Gianotti B. Cutaneous lymphoma: a clinically relevant classification. Int J Dermatol 1993; 32: 695.
5. Burg G, Dummer R, Nestle F, et al. Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Arch Dermatol 1996; 132: 567.
6. Ackerman AB, Schiff TA. If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an "abortive" one, it must be mycosis fungoides. Arch Dermatol 1996; 132: 562-566.
7. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
8. King-Ismael D, Ackerman AB. Guttate parapsoriasis/digitate dermatosis (small plaque parapsoriasis) is mycosis fungoides. Am J Dermatopathol 1992; 14: 518-530.
9. Bunn PJ, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63: 725-728.
10. Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-425.
11. Weinstock MA, Horn JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. J Am Med Assoc 1988; 260: 42.
12. Kim Y, Chow S, Varghese A, et al. Clinical characteristics and long term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26-32.
13. Van Doorn R, Van Haselen CW, Van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-510.
14. Herrmann JJ, Roenigk HH, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Dermatol Clin 1995; 9: 1077-1087.
15. Hönigsmann H. PUVA therapie der mycosis fungoides. Akt Dermatol 1987; 13: 78.
16. Bunn PA, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
17. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T cell lymphoma. Dermatol Clin 1995; 9: 1089-1107.
18. Dreno B. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells 1993; 11: 269-275.
19. Apisarnthanarax N, Duvic M. Cutaneous T-cell lymphoma, new immunomodulators. Dermatol Clin 2001; 19: 737-748.
20. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon 2a plus acitretin versus interferon 2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-3581.
21. Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa 2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995; 13: 257-263.
22. Rupoli S, Barulli S, Guiducci B, et al. Low dose interferon-2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Haematologica 1999; 84: 809-813.
23. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Clin North Am 1995; 9: 1109-1115.
24. Mielke V, Staib G, Sterry W. Systemic treatment for cutaneous lymphomas. Recent Results Cancer Res 1995; 139: 403-408.
25. Zackheim HS. Cutaneous T cell lymphoma. Update of treatment. Dermatology 1999; 199: 102-105.
26. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113: 185-187.
27. Coninck EC, Kim YH, Varghese A, et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19: 779-784.
28. Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991; 9: 565-571.
29. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603-2606.
30. Tosi P, Pellacani S, Zinzani PL, et al. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 1999; 84: 794-798.
31. Greiner D, Olsen EA, Petroni G. Pentostatin (2-deoxyformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997; 36: 950-955.
32. Foss FM. Activity of pentostatin in cutaneous T-cell lymphoma: single-agent and combination studies. Semin Oncol 2000; 27: 58-63.
33. Toro JR, Stoll HL, Stomper PC, et al. Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome. J Am Acad Dermatol 1997; 37: 58-67.
34. Kim YH, Bishop K, Varghese A, et al. Prognostic factors in erythrodermic mycosis fungoides and Sezary syndrome. Arch Dermatol 1995; 131: 1003-1008.